Pegylated interferon-associated retinopathy in chronic hepatitis C patients.
Ogata
Hiroko
H
Suzuki
Hiromasa
H
Shimizu
Kimiya
K
Ishikawa
Hitoshi
H
Izumi
Namiki
N
Kurosaki
Masayuki
M
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced* / Q000453:epidemiology
D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a